{"transactions":[{"id":2236078,"issuer":{"id":109857,"kind":"organization","name":"Surface Oncology, Inc.","symbol":"SURF"},"owners":[{"id":12398,"kind":"person","name":"Shanafelt Armen","position":1,"cik":"0001656151","reported_name":"Shanafelt Armen","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-10T20:00:46.000Z","date":"2022-06-08","kind":"grant","acquired":true,"shares":24000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Options shall vest in twelve equal monthly installments following the date of grant or, if earlier, upon the date of the next Annual Meeting; provided, however, that all vesting shall cease if the director resigns from the Board of Directors or otherwise ceases to serve as a director, unless the Board of Directors determines that the circumstances warrant continuation of vesting."}],"balance_after":24000,"derivative":{"exercise_price":2.01,"expiration_date":"2032-06-08","underlying":"Common Stock","underlying_shares":24000},"source":{"system":"sec-edgar","filing":"0001209191-22-036150","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1718108/000120919122036150/doc4.xml","form_type":"4"}},{"id":2237765,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":12398,"kind":"person","name":"Shanafelt Armen","position":1,"cik":"0001656151","reported_name":"Shanafelt Armen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2022-06-09T21:22:33.000Z","date":"2022-06-07","kind":"grant","acquired":true,"shares":43000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable in 12 equal monthly installments beginning on July 7, 2022, or on the date of the next annual meeting of stockholders, if earlier, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":43000,"derivative":{"exercise_price":0.73,"expiration_date":"2032-06-06","underlying":"Common Stock","underlying_shares":43000},"source":{"system":"sec-edgar","filing":"0001209191-22-035690","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1656151/000120919122035690/doc4.xml","form_type":"4"}},{"id":2475543,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":12398,"kind":"person","name":"Shanafelt Armen","position":1,"cik":"0001656151","reported_name":"Shanafelt Armen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-13T20:41:12.000Z","date":"2021-12-13","kind":"purchase","acquired":true,"shares":14685,"price":3.65,"value":53600.25,"ownership":{"direct":true},"balance_after":150000,"source":{"system":"sec-edgar","filing":"0001209191-21-069351","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1656151/000120919121069351/doc4.xml","form_type":"4"}},{"id":2475542,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":12398,"kind":"person","name":"Shanafelt Armen","position":1,"cik":"0001656151","reported_name":"Shanafelt Armen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-13T20:41:12.000Z","date":"2021-12-10","kind":"purchase","acquired":true,"shares":13516,"price":3.65,"value":49333.4,"ownership":{"direct":true},"balance_after":135315,"source":{"system":"sec-edgar","filing":"0001209191-21-069351","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1656151/000120919121069351/doc4.xml","form_type":"4"}},{"id":2475541,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":12398,"kind":"person","name":"Shanafelt Armen","position":1,"cik":"0001656151","reported_name":"Shanafelt Armen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-13T20:41:12.000Z","date":"2021-12-09","kind":"purchase","acquired":true,"shares":121799,"price":3.668,"value":446758.732,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.53 to $3.75 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares purchased at each separate price within the range set forth herein."}],"balance_after":121799,"source":{"system":"sec-edgar","filing":"0001209191-21-069351","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1656151/000120919121069351/doc4.xml","form_type":"4"}},{"id":2674015,"issuer":{"id":109857,"kind":"organization","name":"Surface Oncology, Inc.","symbol":"SURF"},"owners":[{"id":12398,"kind":"person","name":"Shanafelt Armen","position":1,"cik":"0001656151","reported_name":"Shanafelt Armen","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-10T16:30:18.000Z","date":"2021-06-08","kind":"grant","acquired":true,"shares":17700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Options shall vest in full upon the earlier to occur of the first anniversary of the date of grant or the date of the next Annual Meeting; provided, however, that all vesting shall cease if the director resigns from the Board of Directors or otherwise ceases to serve as a director, unless the Board of Directors determines that the circumstances warrant continuation of vesting."}],"balance_after":17700,"derivative":{"exercise_price":7.69,"expiration_date":"2031-06-08","underlying":"Common Stock","underlying_shares":17700},"source":{"system":"sec-edgar","filing":"0001209191-21-039460","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1718108/000120919121039460/doc4.xml","form_type":"4"}},{"id":2675660,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":12398,"kind":"person","name":"Shanafelt Armen","position":1,"cik":"0001656151","reported_name":"Shanafelt Armen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2021-06-09T17:27:11.000Z","date":"2021-06-08","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable in 12 equal monthly installments beginning on July 8, 2021, or on the date of the next annual meeting of stockholders, if earlier, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":40000,"derivative":{"exercise_price":6.8,"expiration_date":"2031-06-07","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-21-039233","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1656151/000120919121039233/doc4.xml","form_type":"4"}},{"id":3112042,"issuer":{"id":109857,"kind":"organization","name":"Surface Oncology, Inc.","symbol":"SURF"},"owners":[{"id":12398,"kind":"person","name":"Shanafelt Armen","position":1,"cik":"0001656151","reported_name":"Shanafelt Armen","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-12T08:00:13.000Z","date":"2020-06-10","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in full upon the earlier to occur of the first anniversary of the date of grant or the date of the next Annual Meeting; provided, however, that all vesting shall cease if the director resigns from the Board of Directors or otherwise ceases to serve as a director."}],"balance_after":12000,"derivative":{"exercise_price":4.35,"expiration_date":"2030-06-10","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001209191-20-036175","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1718108/000120919120036175/doc4.xml","form_type":"4"}},{"id":3114831,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":12398,"kind":"person","name":"Shanafelt Armen","position":1,"cik":"0001656151","reported_name":"Shanafelt Armen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2020-06-10T16:39:09.000Z","date":"2020-06-08","kind":"grant","acquired":true,"shares":28100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable in 12 equal monthly installments beginning on July 8, 2020 until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":28100,"derivative":{"exercise_price":8.89,"expiration_date":"2030-06-07","underlying":"Common Stock","underlying_shares":28100},"source":{"system":"sec-edgar","filing":"0001209191-20-035528","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1656151/000120919120035528/doc4.xml","form_type":"4"}},{"id":3398707,"issuer":{"id":109857,"kind":"organization","name":"Surface Oncology, Inc.","symbol":"SURF"},"owners":[{"id":12398,"kind":"person","name":"Shanafelt Armen","position":1,"cik":"0001656151","reported_name":"Shanafelt Armen","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-10-03T16:31:26.000Z","date":"2019-10-01","kind":"grant","acquired":true,"shares":16531,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of retainer and committee fees of $11,875 which would have been paid quarterly. This option shall vest in full on December 31, 2019."}],"balance_after":16531,"derivative":{"exercise_price":1.17,"expiration_date":"2029-10-01","underlying":"Common Stock","underlying_shares":16531},"source":{"system":"sec-edgar","filing":"0001209191-19-052209","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1718108/000120919119052209/doc4.xml","form_type":"4"}},{"id":3471467,"issuer":{"id":109857,"kind":"organization","name":"Surface Oncology, Inc.","symbol":"SURF"},"owners":[{"id":12398,"kind":"person","name":"Shanafelt Armen","position":1,"cik":"0001656151","reported_name":"Shanafelt Armen","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-07-02T17:20:10.000Z","date":"2019-07-01","kind":"grant","acquired":true,"shares":6937,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was issued to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of retainer and committee fees of $11,875 which would have been paid quarterly. This option shall vest in full on September 30, 2019."}],"balance_after":6937,"derivative":{"exercise_price":2.79,"expiration_date":"2029-07-01","underlying":"Common Stock","underlying_shares":6937},"source":{"system":"sec-edgar","filing":"0001209191-19-040468","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1718108/000120919119040468/doc4.xml","form_type":"4"}},{"id":3497236,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":12398,"kind":"person","name":"Shanafelt Armen","position":1,"cik":"0001656151","reported_name":"Shanafelt Armen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2019-06-07T16:51:18.000Z","date":"2019-06-07","kind":"grant","acquired":true,"shares":12400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable in 12 equal monthly installments beginning on July 7, 2019 until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":12400,"derivative":{"exercise_price":6.33,"expiration_date":"2029-06-06","underlying":"Common Stock","underlying_shares":12400},"source":{"system":"sec-edgar","filing":"0001567619-19-013073","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1656151/000156761919013073/doc1.xml","form_type":"4"}},{"id":3499076,"issuer":{"id":109857,"kind":"organization","name":"Surface Oncology, Inc.","symbol":"SURF"},"owners":[{"id":12398,"kind":"person","name":"Shanafelt Armen","position":1,"cik":"0001656151","reported_name":"Shanafelt Armen","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-06-06T16:45:41.000Z","date":"2019-06-05","kind":"grant","acquired":true,"shares":12100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in full upon the earlier to occur of the first anniversary of the date of grant or the date of the next Annual Meeting; provided, however, that all vesting shall cease if the director resigns from the Board of Directors or otherwise ceases to serve as a director."}],"balance_after":12100,"derivative":{"exercise_price":3.69,"expiration_date":"2029-06-05","underlying":"Common Stock","underlying_shares":12100},"source":{"system":"sec-edgar","filing":"0001209191-19-035102","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1718108/000120919119035102/doc4.xml","form_type":"4"}},{"id":3884114,"issuer":{"id":7071,"kind":"organization","name":"Rein Therapeutics, Inc."},"owners":[{"id":12398,"kind":"person","name":"Shanafelt Armen","position":1,"cik":"0001656151","reported_name":"Shanafelt Armen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-06-25T18:25:49.000Z","date":"2018-06-21","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 21, 2018. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 21, 2019 or (ii) the date of the Issuer's 2019 Annual Meeting of Stockholders."}],"balance_after":10000,"derivative":{"exercise_price":6.02,"expiration_date":"2028-06-20","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000899243-18-017977","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1656151/000089924318017977/doc4.xml","form_type":"4"}},{"id":3896880,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":12398,"kind":"person","name":"Shanafelt Armen","position":1,"cik":"0001656151","reported_name":"Shanafelt Armen","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-06-12T18:50:17.000Z","date":"2018-05-29","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest at the earlier on (i) May 29, 2019, or (ii) the date of the 2019 Annual Meeting of stockholders of the Issuer, subject to the non-employee director's continuous service with the Issuer through such dates. The shares subject to this option will vest in full upon completion of a Change in Control (as defined in the Issuer's 2016 Equity Incentive Plan)."}],"balance_after":12000,"derivative":{"exercise_price":6.98,"expiration_date":"2028-05-28","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001209191-18-037316","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1656151/000120919118037316/doc4.xml","form_type":"4"}},{"id":3900058,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":12398,"kind":"person","name":"Shanafelt Armen","position":1,"cik":"0001656151","reported_name":"Shanafelt Armen","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2018-06-08T18:47:00.000Z","date":"2018-06-07","kind":"grant","acquired":true,"shares":18400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable in 12 equal monthly installments beginning on July 7, 2018 until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":18400,"derivative":{"exercise_price":10.28,"expiration_date":"2028-06-06","underlying":"Common Stock","underlying_shares":18400},"source":{"system":"sec-edgar","filing":"0001140361-18-027931","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1656151/000114036118027931/doc1.xml","form_type":"4"}},{"id":3958641,"issuer":{"id":109857,"kind":"organization","name":"Surface Oncology, Inc.","symbol":"SURF"},"owners":[{"id":12398,"kind":"person","name":"Shanafelt Armen","position":1,"cik":"0001656151","reported_name":"Shanafelt Armen","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2018-04-23T16:16:01.000Z","date":"2018-04-23","kind":"exercise","acquired":false,"shares":7000000,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series A Preferred Stock automatically converted into the Issuer's common stock on a 2.2-for-1 basis at the closing of the Issuer's initial public\noffering  without payment or further consideration and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series A Preferred Stock automatically converted into the Issuer's common stock on a 2.2-for-1 basis at the closing of the Issuer's initial public\noffering  without payment or further consideration and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series A Preferred Stock automatically converted into the Issuer's common stock on a 2.2-for-1 basis at the closing of the Issuer's initial public\noffering  without payment or further consideration and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series A Preferred Stock automatically converted into the Issuer's common stock on a 2.2-for-1 basis at the closing of the Issuer's initial public\noffering  without payment or further consideration and had no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The Series A Preferred Stock automatically converted into the Issuer's common stock on a 2.2-for-1 basis at the closing of the Issuer's initial public\noffering  without payment or further consideration and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Lilly Ventures Fund I, LLC (LVFI). LV Management Group, LLC (LVMG) is the management company for LVFI and has voting and dispositive power over the shares held by LVFI. As such, LVMG may be deemed to indirectly beneficially own the shares held by LVFI. LVMG's voting and dispositive decisions with respect to the shares held by LVFI are made by LVMG's management committee, which includes the Reporting Person.  The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3181817},"source":{"system":"sec-edgar","filing":"0001209191-18-025823","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1718108/000120919118025823/doc4.xml","form_type":"4"}},{"id":3958640,"issuer":{"id":109857,"kind":"organization","name":"Surface Oncology, Inc.","symbol":"SURF"},"owners":[{"id":12398,"kind":"person","name":"Shanafelt Armen","position":1,"cik":"0001656151","reported_name":"Shanafelt Armen","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-04-23T16:16:01.000Z","date":"2018-04-23","kind":"purchase","acquired":true,"shares":266000,"price":15,"value":3990000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Lilly Ventures Fund I, LLC (LVFI). LV Management Group, LLC (LVMG) is the management company for LVFI and has voting and dispositive power over the shares held by LVFI. As such, LVMG may be deemed to indirectly beneficially own the shares held by LVFI. LVMG's voting and dispositive decisions with respect to the shares held by LVFI are made by LVMG's management committee, which includes the Reporting Person.  The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein."}],"balance_after":3447817,"source":{"system":"sec-edgar","filing":"0001209191-18-025823","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1718108/000120919118025823/doc4.xml","form_type":"4"}},{"id":3958639,"issuer":{"id":109857,"kind":"organization","name":"Surface Oncology, Inc.","symbol":"SURF"},"owners":[{"id":12398,"kind":"person","name":"Shanafelt Armen","position":1,"cik":"0001656151","reported_name":"Shanafelt Armen","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-04-23T16:16:01.000Z","date":"2018-04-23","kind":"exercise","acquired":true,"shares":3181817,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series A Preferred Stock automatically converted into the Issuer's common stock on a 2.2-for-1 basis at the closing of the Issuer's initial public\noffering  without payment or further consideration and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Lilly Ventures Fund I, LLC (LVFI). LV Management Group, LLC (LVMG) is the management company for LVFI and has voting and dispositive power over the shares held by LVFI. As such, LVMG may be deemed to indirectly beneficially own the shares held by LVFI. LVMG's voting and dispositive decisions with respect to the shares held by LVFI are made by LVMG's management committee, which includes the Reporting Person.  The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein."}],"balance_after":3181817,"source":{"system":"sec-edgar","filing":"0001209191-18-025823","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1718108/000120919118025823/doc4.xml","form_type":"4"}},{"id":4142119,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":12398,"kind":"person","name":"Shanafelt Armen","position":1,"cik":"0001656151","reported_name":"Shanafelt Armen","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2017-12-05T21:06:04.000Z","date":"2017-12-01","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable in 12 equal monthly installments beginning on January 1, 2018 until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":30000,"derivative":{"exercise_price":4.73,"expiration_date":"2027-11-30","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001140361-17-045128","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1656151/000114036117045128/doc1.xml","form_type":"4"}},{"id":4250184,"issuer":{"id":7071,"kind":"organization","name":"Rein Therapeutics, Inc."},"owners":[{"id":12398,"kind":"person","name":"Shanafelt Armen","position":1,"cik":"0001656151","reported_name":"Shanafelt Armen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-07-27T18:30:42.000Z","date":"2017-07-25","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on July 25, 2017.  The shares underlying the option are scheduled to vest in equal annual installments over three years from July 25, 2017."}],"balance_after":20000,"derivative":{"exercise_price":13,"expiration_date":"2027-07-24","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000899243-17-019216","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1656151/000089924317019216/doc4.xml","form_type":"4"}},{"id":4260922,"issuer":{"id":7071,"kind":"organization","name":"Rein Therapeutics, Inc."},"owners":[{"id":12398,"kind":"person","name":"Shanafelt Armen","position":1,"cik":"0001656151","reported_name":"Shanafelt Armen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series F Preferred Stock","published_at":"2017-07-07T19:18:02.000Z","date":"2017-07-05","kind":"exercise","acquired":false,"shares":1443972,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Lilly Ventures Fund I LLC, or LVFI. LV Management Group, LLC, or LVMG, is the management company for LVFI and as such may be deemed to indirectly beneficially own the shares held by LVFI. LVMG's voting and dispositive decisions with respect to the shares held by LVFI are made by LVMG's management committee, which includes the Reporting Person. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his proportionate pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":145312},"source":{"system":"sec-edgar","filing":"0000899243-17-018096","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1656151/000089924317018096/doc4.xml","form_type":"4"}},{"id":4260921,"issuer":{"id":7071,"kind":"organization","name":"Rein Therapeutics, Inc."},"owners":[{"id":12398,"kind":"person","name":"Shanafelt Armen","position":1,"cik":"0001656151","reported_name":"Shanafelt Armen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series E-3 Preferred Stock","published_at":"2017-07-07T19:18:02.000Z","date":"2017-07-05","kind":"exercise","acquired":false,"shares":1654411,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Lilly Ventures Fund I LLC, or LVFI. LV Management Group, LLC, or LVMG, is the management company for LVFI and as such may be deemed to indirectly beneficially own the shares held by LVFI. LVMG's voting and dispositive decisions with respect to the shares held by LVFI are made by LVMG's management committee, which includes the Reporting Person. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his proportionate pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":166489},"source":{"system":"sec-edgar","filing":"0000899243-17-018096","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1656151/000089924317018096/doc4.xml","form_type":"4"}},{"id":4260920,"issuer":{"id":7071,"kind":"organization","name":"Rein Therapeutics, Inc."},"owners":[{"id":12398,"kind":"person","name":"Shanafelt Armen","position":1,"cik":"0001656151","reported_name":"Shanafelt Armen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series E-2 Preferred Stock","published_at":"2017-07-07T19:18:02.000Z","date":"2017-07-05","kind":"exercise","acquired":false,"shares":1907373,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Lilly Ventures Fund I LLC, or LVFI. LV Management Group, LLC, or LVMG, is the management company for LVFI and as such may be deemed to indirectly beneficially own the shares held by LVFI. LVMG's voting and dispositive decisions with respect to the shares held by LVFI are made by LVMG's management committee, which includes the Reporting Person. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his proportionate pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":191946},"source":{"system":"sec-edgar","filing":"0000899243-17-018096","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1656151/000089924317018096/doc4.xml","form_type":"4"}},{"id":4260919,"issuer":{"id":7071,"kind":"organization","name":"Rein Therapeutics, Inc."},"owners":[{"id":12398,"kind":"person","name":"Shanafelt Armen","position":1,"cik":"0001656151","reported_name":"Shanafelt Armen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series D Preferred Stock","published_at":"2017-07-07T19:18:02.000Z","date":"2017-07-05","kind":"exercise","acquired":false,"shares":3390885,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Lilly Ventures Fund I LLC, or LVFI. LV Management Group, LLC, or LVMG, is the management company for LVFI and as such may be deemed to indirectly beneficially own the shares held by LVFI. LVMG's voting and dispositive decisions with respect to the shares held by LVFI are made by LVMG's management committee, which includes the Reporting Person. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his proportionate pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":341238},"source":{"system":"sec-edgar","filing":"0000899243-17-018096","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1656151/000089924317018096/doc4.xml","form_type":"4"}},{"id":4260918,"issuer":{"id":7071,"kind":"organization","name":"Rein Therapeutics, Inc."},"owners":[{"id":12398,"kind":"person","name":"Shanafelt Armen","position":1,"cik":"0001656151","reported_name":"Shanafelt Armen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-07-07T19:18:02.000Z","date":"2017-07-05","kind":"purchase","acquired":true,"shares":250000,"price":15,"value":3750000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Lilly Ventures Fund I LLC, or LVFI. LV Management Group, LLC, or LVMG, is the management company for LVFI and as such may be deemed to indirectly beneficially own the shares held by LVFI. LVMG's voting and dispositive decisions with respect to the shares held by LVFI are made by LVMG's management committee, which includes the Reporting Person. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his proportionate pecuniary interest therein."}],"balance_after":1094987,"source":{"system":"sec-edgar","filing":"0000899243-17-018096","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1656151/000089924317018096/doc4.xml","form_type":"4"}},{"id":4260917,"issuer":{"id":7071,"kind":"organization","name":"Rein Therapeutics, Inc."},"owners":[{"id":12398,"kind":"person","name":"Shanafelt Armen","position":1,"cik":"0001656151","reported_name":"Shanafelt Armen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-07-07T19:18:02.000Z","date":"2017-07-05","kind":"exercise","acquired":true,"shares":844987,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Lilly Ventures Fund I LLC, or LVFI. LV Management Group, LLC, or LVMG, is the management company for LVFI and as such may be deemed to indirectly beneficially own the shares held by LVFI. LVMG's voting and dispositive decisions with respect to the shares held by LVFI are made by LVMG's management committee, which includes the Reporting Person. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his proportionate pecuniary interest therein."}],"balance_after":844987,"source":{"system":"sec-edgar","filing":"0000899243-17-018096","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1656151/000089924317018096/doc4.xml","form_type":"4"}},{"id":4303048,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":12398,"kind":"person","name":"Shanafelt Armen","position":1,"cik":"0001656151","reported_name":"Shanafelt Armen","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-05-26T17:35:37.000Z","date":"2017-05-25","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest at the earlier on (i) May 25, 2018, or (ii) the date of the 2018 Annual Meeting of stockholders of the Issuer, subject to the non-employee director's continuous service with the Issuer through such dates. The shares subject to this option will vest in full upon completion of a Change in Control (as defined in the Issuer's 2016 Equity Incentive Plan)."}],"balance_after":12000,"derivative":{"exercise_price":8.59,"expiration_date":"2027-05-25","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001209191-17-035968","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1656151/000120919117035968/doc4.xml","form_type":"4"}},{"id":4602615,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":12398,"kind":"person","name":"Shanafelt Armen","position":1,"cik":"0001656151","reported_name":"Shanafelt Armen","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2016-09-15T16:26:43.000Z","date":"2016-09-13","kind":"grant","acquired":true,"shares":24000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest in equal monthly installments over a three-year period from the vesting commencement date of August 10, 2016."}],"balance_after":24000,"derivative":{"exercise_price":12.88,"expiration_date":"2026-09-13","underlying":"Common Stock","underlying_shares":24000},"source":{"system":"sec-edgar","filing":"0001209191-16-141592","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1656151/000120919116141592/doc4.xml","form_type":"4"}},{"id":153844,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY","position":1,"cik":"0000059478","reported_name":"LILLY ELI & CO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12397,"kind":"organization","name":"Lilly Ventures Fund I LLC","position":2,"cik":"0001575852","reported_name":"Lilly Ventures Fund I LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12398,"kind":"person","name":"Shanafelt Armen","position":3,"cik":"0001656151","reported_name":"Shanafelt Armen","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2016-04-14T23:35:05.000Z","date":"2016-04-12","kind":"exercise","acquired":true,"shares":2010924,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"by fund"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the consummation of the Issuer's initial public offering on April 12, 2016, each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration, and had no expiration date. All shares of Common Stock issued upon conversion were aggregated."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are owned directly by Lilly Ventures Fund I LLC (the \"Fund\"). LV Management Group LLC (the \"Management Company\") has sole voting and dispositive authority with respect to the shares. Dr. Shanafelt disclaims beneficial ownership of the shares held of record by the Fund, except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This line item is being re-reported in order to gain access to the filing system. This Form is being amended to include Reporting Owners, Lilly Ventures Fund I LLC, and Dr. Shanafelt Armen as beneficial owners of the shares reported in the Form 4, previously filed by Eli Lilly and Company on April 14, 2016."}],"balance_after":2068543,"source":{"system":"sec-edgar","filing":"0000059478-16-000342","document":"wf-form4a_146067689367014.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947816000342/wf-form4a_146067689367014.xml","form_type":"4/A","original_submission_date":"2016-04-14"}}]}